Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 13
- −2 vs. Q1 2024
- Portfolio value
- $885.1M
- −$32.3M (−3.5%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 2,360,077 | $190.0M | 21.5% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 1,924,626 | $146.0M | 16.5% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 4,018,101 | $94.5M | 10.7% | +3,639,680+961.8% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 2,048,647 | $80.6M | 9.1% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,202,798 | $74.8M | 8.5% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,762,837 | $71.5M | 8.1% | 00.0% | Unchanged | History |
| KNSAKiniksa Pharmaceuticals International, plc | ORD SHS CL A | 3,204,841 | $59.8M | 6.8% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,225,641 | $52.5M | 5.9% | +1,500,000+31.7% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 3,554,129 | $32.3M | 3.7% | 00.0% | Unchanged | History |
| PTGXProtagonist Therapeutics, Inc | COM | 931,890 | $32.3M | 3.6% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,845,813 | $24.0M | 2.7% | 00.0% | Unchanged | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 1,069,199 | $21.6M | 2.4% | +1,069,199 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 748,996 | $5.10M | 0.6% | −1,291,004−63.3% | Reduced | History |
Sold out since Q1 2024 (3)
Positions held at the end of Q1 2024 that are gone from this filing.